Capstan Therapeutics. Home; Company; Pipeline; Science & Platform; News & Publications; Company; Science & Platform; Pipeline; Culture & Careers

2022年9月14日 · Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body.

We are a diverse team of experts integrating advancements in CAR-T therapy, mRNA, and LNPs, with rigorous focus to engineer transformative medicines.

SAN DIEGO, March 20, 2024 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of …

2024年11月18日 · Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

2024年9月26日 · Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

SAN DIEGO, JANUARY 8, 2024 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to ...

The Latest from Capstan. Capstan Therapeutics. Home; Company; Pipeline; Science & Platform; News & Publications

Harnessing the biggest and boldest thinking to make a difference for patients, everywhere. Join us on our mission.

Taking the CAR-T modality in vivo, with applications in autoimmunity, oncology, fibrosis, and beyond.